AdamLabs Europe™ ampoules manufacturing video

Ampoule filling and sealing machine is one of the most critical equipment that has significant roles to play in processing of pharmaceutical products especially in liquid injections.

AdamLabs Europe™ tablets manufacturing video

The manufacture of tablets by direct compression is advantageous as the whole process generally requires fewer steps in implementation without requiring the use of moisture and heat. Tablets made as a product of this method have faster dissolution properties as compared to those of wet granulation.

AdamLabs Europe™ vials manufacturing video

Liquid vial filling is a delicate process. Pharmaceutical vial filling machines ensure volumetric consistency, reduce product loss, and feature built in quality control in the form of volume checking.

AdamLabs Europe™. Visual quality control, hologram, protective sleeves.

Presentation of Biprocyne (Testosterone cypionate). The box accommodates 10 ampoules / 1 mL / 200 mg / mL

AdamLabs Europe™ Ravidin boxes on the packaging tape

Pharmaceutical grinding of raw materials video

Before stanozolol raw material enters in the pharmaceutical reactor. It is micronized in a planetary mill. Stanozolol AdamLabs it’s incredibly high quality micronized suspension.

AdamLabs Europe™ ampoule filling and sealing machine. Short video.

AdamLabs Europe™ rotary ampoule washing machine

Presentation AdamLabs Europe™ Rasverol® 10 ml vial/ 100mg/ml ( CAS Number10161-34-9)

Presentation of AdamLabs Europe™ products in tablets

AdamLabs Europe™ Ravidin plastic cells on the packaging tape

Presentation of Ravidin (Testosterone propionate). 10 mL vial / 1 mL / 100 mg / mL

AdamLabs Europe™ ampoule labeling machine video. Labeling and dating

Sources :



3. Short ADAM questionnaire in men.

1. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab. 1972;34:730–735.
2. Rubens R, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab. 1974;39:40–45.
3. Baker HW, Burger HG, de Kretser DM, et al. Changes in the pituitary- testicular system with age. Clin Endocrinol (Oxf). 1976;5:349–372.
4. Pirke KM, Doerr P. Age related changes in free plasma testosterone,
dihydrotestosterone and oestradiol. Acta Endocrinol (Copenh).
5. Purifoy FE, Koopmans LH, Mayes DM. Age differences in serum
androgen levels in normal adult males. Hum Biol. 1981;53:499–511.
6. Bremner WJ, Prinz PN. A loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab.
7. Tenover JS, Matsumoto AM, Plymate SR, Bremner WJ. The effects of
aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab. 1987;65:1118–1126.
8. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol. 1991;44: 671–684.
9. Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998;147:750–754.
10. Harman SM, Tsitouras PD. Reproductive hormones in aging men I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinal Metab. 1980;51:35–40.
11. Morley JE, Kaiser FE, Raum WJ, et al. Potentially predicative and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydro- epiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A. 1997;94: 7537–7542.
12. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73: 1016–1025.
13. Leifke E, Gorenoi V, Wichers C, Von Zur Muhlen A, Von Buren E, Brabant G. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross- sectional data from a healthy male cohort. Clin Endocrinol (Oxf). 2000;53:689–695.
14. Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410–413.
15. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724–731.
16. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovas- cular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol. 1997;146:609–617.
17. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitu- dinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589–598.
18. Davidson JM, Chen JJ, Carpo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983;57:71–77.
19. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242.
20. Morley JE, Perry HM 3rd, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas. 2006;53:424–429.
21. Roy TA, Blackman MR, Harman SM, Tobin JD, Schrager M, Metter EJ.

Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab. 2002;283:E284–E294.
22. Van den Beld AW, de Jong FH, Grobbee DE, Pols HAP, Lamberts SWJ. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85: 3276–3282.
23. Pluijm SM, Smit JH, van Schoor NM, et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf). 2005;63:152–160.
24. Perry HM 3rd, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism. 2000;49:1085–1091.
25. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101–115.
26. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82: 1661–1667.
27. Bhasin S. Testosterone supplementation for aging-associated sarcope- nia. J Gerontol A Biol Sci Med Sci. 2003;58A:1002–1008.
28. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strength in elderly men: a meta- analysis. J Am Geriatr Soc. 2006;54:1666–1673.
29. Cherrier MM, Asthana S, Plymate S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:80–88.
30. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108:325–332.
31. Janowsky JS, Chavez B, Orwoll ES. Sex steroids modify working memory. J Cogn Neurosci. 2000;12:407–414.
32. Morley JE, Patrick P, Perry HM 3rd. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51:554–559.
33. Heineman AJ, Zimmermann J, Vermeulen A, Thiel C. A new ageing males’ symptoms (AMS) rating scale. Aging Male. 1998;2:105–114.
34. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in aging men. Clin Endocrinol. 2000;53:703–711.
35. Lunenfeld B, Saad F, Hoesl CE. ISA, ISSAM and EAU recommen- dations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. Aging Male. 2005;8:59–74.
36. Nieschlag E, Swerdloff R, Behre HM, et al. International Society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU). Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol. 2005;48:1–4.
37. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005;28:125–127.